GLP-1 & Incretin Science

A GLP-1/Glucagon Dual Aimed at the Liver

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Pemvidutide is a dual agonist of the GLP-1 and glucagon receptors. Browne and colleagues published a randomised controlled trial of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease in JHEP Reports in November 2025.

Key facts

Class
GLP-1 / glucagon dual agonist
Trial duration
24 weeks
Condition studied
MASLD
Published
JHEP Rep, November 2025 (PMID 41113119)
Design
Randomised, controlled
Same receptor pair as
Survodutide, mazdutide
Authorisation
None

Why glucagon agonism points at the liver

Glucagon receptor activation increases energy expenditure and mobilises hepatic fat. That second effect is what makes a GLP-1/glucagon dual agonist a liver compound as much as a weight compound, it acts directly on the tissue where steatotic liver disease begins, rather than only reducing the adiposity upstream of it.

Why the liver indication is pursued so hard in this class

Because the mechanism suits it and because the need is substantial. Survodutide and mazdutide share the receptor pair and have both been studied with hepatic endpoints in view. A compound whose glucagon arm mobilises liver fat is being aimed at the organ that arm acts on, which is a more direct rationale than most indication expansion in this field.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

MASLD and MASH are not the same endpoint

Metabolic dysfunction-associated steatotic liver disease covers fat accumulation; steatohepatitis adds inflammation and cell injury. Trials in the two report different things, and the published trial here names MASLD. Reading a steatosis result as though it were a steatohepatitis result overstates it, and the terms are close enough to be conflated easily.

Why 24 weeks fits a liver endpoint better than a weight one

Hepatic fat responds relatively quickly and can be measured by imaging rather than requiring biopsy. Twenty-four weeks is short for a weight-reduction trial and reasonable for a change in liver fat content, which is one reason liver programmes can read out sooner than the histological endpoints described elsewhere on this site.

The glucagon trade-off

Glucagon raises blood glucose, which is why glucagon receptor agonism only works alongside sufficient GLP-1 activity to offset it. The balance between the two arms is the central design parameter, and it is fixed at the molecule level. The same constraint retatrutide faces with its third receptor.

Regulatory position

Pemvidutide holds no marketing authorisation anywhere and is investigational. Nothing supplied on this site is related to it or is an alternative to any treatment for liver disease.

Frequently asked questions

What does pemvidutide target?

The GLP-1 and glucagon receptors, the same pair as survodutide and mazdutide.

Why is it studied in liver disease?

Glucagon receptor agonism mobilises hepatic fat, so the mechanism acts directly on the tissue where steatotic liver disease begins.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.